ScholarIQanswers from OpenAlex & ORCID
Thomas Kaley
ResearcherPublications, citations & collaboration network
Thomas Kaley is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Thomas Kaley have?
ScholarIQindexed works
Thomas Kaley has 251 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Thomas Kaley have?
ScholarIQcitation count
Thomas Kaley has 16,372 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Thomas Kaley?
ScholarIQh-index
Thomas Kaley has an h-index of 44 in OpenAlex.
What is the i10-index of Thomas Kaley?
ScholarIQi10-index
Thomas Kaley has an i10-index of 71 in OpenAlex.
What is the ORCID of Thomas Kaley?
ScholarIQorcid
The ORCID for Thomas Kaley is on the source record.
What is the OpenAlex record for Thomas Kaley?
ScholarIQopenalex
The OpenAlex for Thomas Kaley is on the source record.
What are the most-cited papers on Thomas Kaley?
ScholarIQmost cited works
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen, Yelena Y. Janjigian, David Barron, Ahmet Zehir, Emmet Jordan, Antonio Omuro, Thomas Kaley, Sviatoslav M. Kendall, Robert J. Motzer, A. Ari Hakimi, Martin H. Voss, Paul Russo, Jonathan E. Rosenberg, Gopa Iyer, Bernard H. Bochner, Dean F. Bajorin, Hikmat Al‐Ahmadie, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Shrujal S. Baxi, Alan L. Ho, Richard J. Wong, David G. Pfister, Jedd D. Wolchok, Christopher A. Barker, Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris
OncoKB: A Precision Oncology Knowledge Base
Debyani Chakravarty, Jianjiong Gao, Sarah Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E. Rudolph, Rona Yaeger, Tara E. Soumerai, Moriah H. Nissan, Matthew T. Chang, Sarat Chandarlapaty, Tiffany A. Traina, Paul K. Paik, Alan L. Ho, Feras Hantash, Andrew Grupe, Shrujal S. Baxi, Margaret K. Callahan, Alexandra Snyder, Ping Chi, Daniel C. Danila, Mrinal M. Gounder, James J. Harding, Matthew D. Hellmann, Gopa Iyer, Yelena Y. Janjigian, Thomas Kaley, Douglas A. Levine, Maeve A. Lowery, Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla, Willy Hugo, Alex Lee, Tom B. Davidson, Anthony Wang, Benjamin M. Ellingson, Julie Rytlewski, Catherine Sanders, Eric S. Kawaguchi, Lin Du, Gang Li, William H. Yong, Sarah Gaffey, Adam L. Cohen, Ingo K. Mellinghoff, Eudocia Q. Lee, David A. Reardon, Barbara O’Brien, Nicholas Butowski, Phioanh L. Nghiemphu, Jennifer Clarke, Isabel Arrillaga‐Romany, Howard Colman, Thomas Kaley, John de Groot, Linda M. Liau, Patrick Y. Wen, Robert M. Prins
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Burt Nabors, Jana Portnow, Manmeet S. Ahluwalia, Joachim M. Baehring, Henry Brem, Steven Brem, Nicholas Butowski, Jian Campian, Stephen W. Clark, Andrew J. Fabiano, Peter Forsyth, Jona A. Hattangadi‐Gluth, Matthias Holdhoff, Craig Horbinski, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Maciej M. Mrugała, Seema Nagpal, Manjari Pandey, Ian F. Parney, Katherine B. Peters, Vinay K. Puduvalli, Ian Robins, Jason K. Rockhill, Chad G. Rusthoven, Nicole Shonka, Dennis C. Shrieve, Lode J. Swinnen, Stephanie E. Weiss, Patrick Y. Wen, Nicole E. Willmarth, Mary Anne Bergman, Susan Darlow
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Coté, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, David A. Reardon